Eintrag weiter verarbeiten
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , |
| In: | Journal of Clinical Oncology, 35, 2017, 11, S. 1240-1249 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Lheureux, Stephanie Bruce, Jeff P. Burnier, Julia V. Karakasis, Katherine Shaw, Patricia A. Clarke, Blaise A. Yang, S.Y. Cindy Quevedo, Rene Li, Tiantian Dowar, Mark Bowering, Valerie Pugh, Trevor J. Oza, Amit M. Lheureux, Stephanie Bruce, Jeff P. Burnier, Julia V. Karakasis, Katherine Shaw, Patricia A. Clarke, Blaise A. Yang, S.Y. Cindy Quevedo, Rene Li, Tiantian Dowar, Mark Bowering, Valerie Pugh, Trevor J. Oza, Amit M. |
|---|---|
| author |
Lheureux, Stephanie Bruce, Jeff P. Burnier, Julia V. Karakasis, Katherine Shaw, Patricia A. Clarke, Blaise A. Yang, S.Y. Cindy Quevedo, Rene Li, Tiantian Dowar, Mark Bowering, Valerie Pugh, Trevor J. Oza, Amit M. |
| spellingShingle |
Lheureux, Stephanie Bruce, Jeff P. Burnier, Julia V. Karakasis, Katherine Shaw, Patricia A. Clarke, Blaise A. Yang, S.Y. Cindy Quevedo, Rene Li, Tiantian Dowar, Mark Bowering, Valerie Pugh, Trevor J. Oza, Amit M. Journal of Clinical Oncology Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition Cancer Research Oncology |
| author_sort |
lheureux, stephanie |
| spelling |
Lheureux, Stephanie Bruce, Jeff P. Burnier, Julia V. Karakasis, Katherine Shaw, Patricia A. Clarke, Blaise A. Yang, S.Y. Cindy Quevedo, Rene Li, Tiantian Dowar, Mark Bowering, Valerie Pugh, Trevor J. Oza, Amit M. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2016.71.3677 <jats:sec><jats:title>Purpose</jats:title><jats:p> Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are observed in patients without BRCA1/2 mutations. However, beyond BRCA1/2 mutations, there are no approved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC). To determine mechanisms of durable response and resistance to olaparib therapy, we performed an analysis of HGSOC tumors from three patients without germline BRCA1/2 mutations who experienced exceptional responses to olaparib. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We performed integrated exome, low-pass genome, and RNA sequence analysis of tumors at diagnosis and upon relapse from patients with platinum-sensitive HGSOC recurrence who were treated > 5 years with olaparib therapy as a single agent. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> We observed somatic disruption of BRCA1/2 in all three patients at diagnosis, followed by subsequent BRCA recovery upon progression by copy number gain and/or upregulation of the remaining functional allele in two patients. The third patient with ongoing response (> 7 years) had a tumor at diagnosis with biallelic somatic deletion and loss-of-function mutation, thereby lacking a functional allele for recovery of BRCA1 activity and indicating a potential cure. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Olaparib has durable benefit for patients with ovarian cancer beyond germline BRCA1/2 carriers. These data suggest that biallelic loss of BRCA1/2 in cancer cells may be a potential marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restoration of homologous repair function may be a mechanism of disease resistance. </jats:p></jats:sec> Somatic <i>BRCA1/2</i> Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2016.71.3677 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNi43MS4zNjc3 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNi43MS4zNjc3 |
| institution |
DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 |
| imprint |
American Society of Clinical Oncology (ASCO), 2017 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2017 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
lheureux2017somaticbrca12recoveryasaresistancemechanismafterexceptionalresponsetopolyadpribosepolymeraseinhibition |
| publishDateSort |
2017 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_unstemmed |
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_full |
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_fullStr |
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_full_unstemmed |
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_short |
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_sort |
somatic <i>brca1/2</i> recovery as a resistance mechanism after exceptional response to poly (adp-ribose) polymerase inhibition |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2016.71.3677 |
| publishDate |
2017 |
| physical |
1240-1249 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p> Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are observed in patients without BRCA1/2 mutations. However, beyond BRCA1/2 mutations, there are no approved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC). To determine mechanisms of durable response and resistance to olaparib therapy, we performed an analysis of HGSOC tumors from three patients without germline BRCA1/2 mutations who experienced exceptional responses to olaparib. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We performed integrated exome, low-pass genome, and RNA sequence analysis of tumors at diagnosis and upon relapse from patients with platinum-sensitive HGSOC recurrence who were treated > 5 years with olaparib therapy as a single agent. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> We observed somatic disruption of BRCA1/2 in all three patients at diagnosis, followed by subsequent BRCA recovery upon progression by copy number gain and/or upregulation of the remaining functional allele in two patients. The third patient with ongoing response (> 7 years) had a tumor at diagnosis with biallelic somatic deletion and loss-of-function mutation, thereby lacking a functional allele for recovery of BRCA1 activity and indicating a potential cure. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Olaparib has durable benefit for patients with ovarian cancer beyond germline BRCA1/2 carriers. These data suggest that biallelic loss of BRCA1/2 in cancer cells may be a potential marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restoration of homologous repair function may be a mechanism of disease resistance. </jats:p></jats:sec> |
| container_issue |
11 |
| container_start_page |
1240 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
35 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346316052889605 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:37:18.063Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Somatic+BRCA1%2F2+Recovery+as+a+Resistance+Mechanism+After+Exceptional+Response+to+Poly+%28ADP-ribose%29+Polymerase+Inhibition&rft.date=2017-04-10&genre=article&issn=1527-7755&volume=35&issue=11&spage=1240&epage=1249&pages=1240-1249&jtitle=Journal+of+Clinical+Oncology&atitle=Somatic+%3Ci%3EBRCA1%2F2%3C%2Fi%3E+Recovery+as+a+Resistance+Mechanism+After+Exceptional+Response+to+Poly+%28ADP-ribose%29+Polymerase+Inhibition&aulast=Oza&aufirst=Amit+M.&rft_id=info%3Adoi%2F10.1200%2Fjco.2016.71.3677&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346316052889605 |
| author | Lheureux, Stephanie, Bruce, Jeff P., Burnier, Julia V., Karakasis, Katherine, Shaw, Patricia A., Clarke, Blaise A., Yang, S.Y. Cindy, Quevedo, Rene, Li, Tiantian, Dowar, Mark, Bowering, Valerie, Pugh, Trevor J., Oza, Amit M. |
| author_facet | Lheureux, Stephanie, Bruce, Jeff P., Burnier, Julia V., Karakasis, Katherine, Shaw, Patricia A., Clarke, Blaise A., Yang, S.Y. Cindy, Quevedo, Rene, Li, Tiantian, Dowar, Mark, Bowering, Valerie, Pugh, Trevor J., Oza, Amit M., Lheureux, Stephanie, Bruce, Jeff P., Burnier, Julia V., Karakasis, Katherine, Shaw, Patricia A., Clarke, Blaise A., Yang, S.Y. Cindy, Quevedo, Rene, Li, Tiantian, Dowar, Mark, Bowering, Valerie, Pugh, Trevor J., Oza, Amit M. |
| author_sort | lheureux, stephanie |
| container_issue | 11 |
| container_start_page | 1240 |
| container_title | Journal of Clinical Oncology |
| container_volume | 35 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p> Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are observed in patients without BRCA1/2 mutations. However, beyond BRCA1/2 mutations, there are no approved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC). To determine mechanisms of durable response and resistance to olaparib therapy, we performed an analysis of HGSOC tumors from three patients without germline BRCA1/2 mutations who experienced exceptional responses to olaparib. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We performed integrated exome, low-pass genome, and RNA sequence analysis of tumors at diagnosis and upon relapse from patients with platinum-sensitive HGSOC recurrence who were treated > 5 years with olaparib therapy as a single agent. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> We observed somatic disruption of BRCA1/2 in all three patients at diagnosis, followed by subsequent BRCA recovery upon progression by copy number gain and/or upregulation of the remaining functional allele in two patients. The third patient with ongoing response (> 7 years) had a tumor at diagnosis with biallelic somatic deletion and loss-of-function mutation, thereby lacking a functional allele for recovery of BRCA1 activity and indicating a potential cure. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Olaparib has durable benefit for patients with ovarian cancer beyond germline BRCA1/2 carriers. These data suggest that biallelic loss of BRCA1/2 in cancer cells may be a potential marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restoration of homologous repair function may be a mechanism of disease resistance. </jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2016.71.3677 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNi43MS4zNjc3 |
| imprint | American Society of Clinical Oncology (ASCO), 2017 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2017 |
| institution | DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T17:37:18.063Z |
| match_str | lheureux2017somaticbrca12recoveryasaresistancemechanismafterexceptionalresponsetopolyadpribosepolymeraseinhibition |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 1240-1249 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Lheureux, Stephanie Bruce, Jeff P. Burnier, Julia V. Karakasis, Katherine Shaw, Patricia A. Clarke, Blaise A. Yang, S.Y. Cindy Quevedo, Rene Li, Tiantian Dowar, Mark Bowering, Valerie Pugh, Trevor J. Oza, Amit M. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2016.71.3677 <jats:sec><jats:title>Purpose</jats:title><jats:p> Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are observed in patients without BRCA1/2 mutations. However, beyond BRCA1/2 mutations, there are no approved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC). To determine mechanisms of durable response and resistance to olaparib therapy, we performed an analysis of HGSOC tumors from three patients without germline BRCA1/2 mutations who experienced exceptional responses to olaparib. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We performed integrated exome, low-pass genome, and RNA sequence analysis of tumors at diagnosis and upon relapse from patients with platinum-sensitive HGSOC recurrence who were treated > 5 years with olaparib therapy as a single agent. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> We observed somatic disruption of BRCA1/2 in all three patients at diagnosis, followed by subsequent BRCA recovery upon progression by copy number gain and/or upregulation of the remaining functional allele in two patients. The third patient with ongoing response (> 7 years) had a tumor at diagnosis with biallelic somatic deletion and loss-of-function mutation, thereby lacking a functional allele for recovery of BRCA1 activity and indicating a potential cure. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Olaparib has durable benefit for patients with ovarian cancer beyond germline BRCA1/2 carriers. These data suggest that biallelic loss of BRCA1/2 in cancer cells may be a potential marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restoration of homologous repair function may be a mechanism of disease resistance. </jats:p></jats:sec> Somatic <i>BRCA1/2</i> Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition Journal of Clinical Oncology |
| spellingShingle | Lheureux, Stephanie, Bruce, Jeff P., Burnier, Julia V., Karakasis, Katherine, Shaw, Patricia A., Clarke, Blaise A., Yang, S.Y. Cindy, Quevedo, Rene, Li, Tiantian, Dowar, Mark, Bowering, Valerie, Pugh, Trevor J., Oza, Amit M., Journal of Clinical Oncology, Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition, Cancer Research, Oncology |
| title | Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_full | Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_fullStr | Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_full_unstemmed | Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_short | Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| title_sort | somatic <i>brca1/2</i> recovery as a resistance mechanism after exceptional response to poly (adp-ribose) polymerase inhibition |
| title_unstemmed | Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2016.71.3677 |